Malignancy as a solid-phase coagulopathy: Implications for the etiology, pathogenesis, and treatment of cancer

Seminars in Thrombosis and Hemostasis

Volumn 29, Issue 3, 2003, Pages 239-246

  Zacharski, Leo R ^a,b,c  

^a Department of Veterans Affairs Regional Office White River Junction   (United States)

^b VA MEDICAL CENTER   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Anticoagulants; Blood coagulation; Cancer treatment; Malignancy

Indexed keywords

ANTICOAGULANT THERAPY; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CANCER; CANCER CELL; CANCER GROWTH; CANCER PREVENTION; CANCER RELATED THROMBOSIS; CANCER THERAPY; CELL TRANSFORMATION; DISEASE COURSE; HEMOSTASIS; MALIGNANT TRANSFORMATION; OUTCOMES RESEARCH; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SOLID PHASE COAGULOPATHY; THROMBOSIS; TUMOR GROWTH;

ANTICOAGULANTS; BLOOD COAGULATION; HUMANS; NEOPLASMS; THROMBOPHILIA;

EID: 0038772361     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-40962     Document Type: Review

References (50)

1. Rickles FR, Levine MN, Dvorak HF. Abnormalities of hemostasis in malignancy. In: Colman RW, Hirsh J, Marder VJ, et al, eds. Hemostasis and Thrombosis. Basic Principles and Clinical Practice, 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:1132-1152
2. Burnes J. Dissertations on Inflammation, Vol, I. Albany, NY: EF Backus; 1812
3. DeVita VA, Hellman S, Rosenberg RA, eds. Cancer: Principles & Practice of Oncology, 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001
4. Zacharski LR, Wojtukiewicz MZ, Costantini V, Ornstein DL, Memoli VA. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemost 1992;18:104-116
5. Meehan KR, Zacharski LR, Moritz TE, Rickles FR. Pretreatment fibrinogen levels predict response to chemotherapy in small cell carcinoma of the lung. Am J Hematol 1995;49:143-148
6. Milroy R, Douglas JT, Campbell J, et al. Abnormal haemostasis in small cell lung cancer. Thorax 1988;43:978-981
7. Costantini V, Zacharski LR, Memoli VA, et al. Fibrinogen deposition and macrophage-associated fibrin formation in malignant and non-malignant lymphoid tissue. J Lab Clin Med 1992;119:124-131
8. Thodiyil PA, Kakkar AK. Variation in relative risk of venous thromboembolism in various cancers. Thromb Haemost 2002;87:1076-1077
9. Costantini V, Zacharski LR, Memoli VA, et al. Fibrinogen deposition without thrombin generation in primary human breast cancer tissue. Cancer Res 1991;51:349-353
10. Costantini V, Zacharski LR, Memoli VA, et al. Occurrence of components of fibrinolysis pathways in situ in neoplastic and non-neoplastic human breast tissue. Cancer Res 1991;51:354-358
11. Korte W. Changes in the coagulation and fibrinolysis system in malignancy: their possible impact on future diagnostic and therapeutic procedures. Clin Chem Lab Med 2000;38:679-692
12. Edwards RL, Rickles FR, Moritz TE, et al. Abnormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol 1987;88:596-602
13. Deitscher SR. Cancer-related deep venous thrombosis: clinical importance, treatment challenges and management strategies. Semin Thromb Hemost 2003;29:247-258
14. Francis JL, Amirkhosravi A. Effect of antimetastatic agents on experimental tumor dissemination. Semin Thromb Hemost 2002;28:29-38
15. Dembski WA, Kushiner JM, eds. Signs of Intelligence. Grand Rapids, MI: Brazos Press; 2001
16. Pihusch R, Danzl G, Scholz M, et al. Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. Cancer 200;94:3120-3126
17. Liu D, Shriver Z, Venkataraman G, Shabrawi Y, Sasisekharan R. Tumor cell surface heparan sulfate as cryptic promoters of inhibitors of tumor growth and metastasis. Proc Natl Acad Sci USA 2002;99:568-573
18. Richmond RA, Thomas HG. Melanoma growth stimulating activity: isolation from human melanoma tumors and characterization of tissue distribution. J Cell Biochem 1988;36:185-198
19. Zugmaier G, Favoni R, Jaeger R, Rosen N, Knabbe C. Polysulfated heparinoids selectively inactivate heparin-binding angiogenic factors. Ann NY Acad Sci 1999;886:243-248
20. Zacharski LR, Loynes JR, Ornstein DL, Rigas JR. The plasminogen system and cancer. Biomed Prog 2002;15:17-22
21. Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Haemost 1998;80:10-23
22. Lentschener C, Li CH, Franco D, et al. Intraoperatively-administered aprotinin and survival after elective liver resection for colorectal cancer metastasis. A preliminary study. Fibrinolysis Proteolysis 1999;13:39-45
23. Zacharski LR, Morain WD, Schlaeppi J-M, Memoli VA, Rousseau SM. Cellular localization of enzymatically active thrombin in intact human tissue by hirudin binding. Thromb Haemost 1995;73:793-797
24. Coughlin SR. Thrombin signaling and protease-activated receptors. Nature 2000;407:258-264
25. Mousa SA. Anticoagulants in thrombosis and cancer: the missing link. Semin Thromb Hemost 2002;28:45-52
26. Trikha M, Nakada MT. Platelets and cancer: implications for antiangiogenic therapy. Semin Thromb Hemost 2002;28:39-44
27. Dunbar SD, Ornstein DL, Zacharski LR. Cancer treatment with inhibitors of urokinase-type plasminogen activator and plasmin. Exp Opin Invest Drugs 2000;9:2085-2092
28. Wojtukiewicz MZ, Rucinska M, Zacharski LR, et al. Blood coagulation activation in situ in pancreatic cancer tissue. Thromb Haemost 2001;86:1416-1420
29. Zacharski LR, Ornstein DL, Gabazza EC, et al. Treatment of malignancy by activation of the plasminogen system. Semin Thromb Hemost 2002;28:5-17
30. Zacharski LR, Donati MB, Rickles FR. Registry of clinical trials of antithrombotic drugs in cancer: second report. Thromb Haemost 1993;70:357-360
31. Ornstein DL, Zacharski LR. Treatment of cancer with anticoagulants: rationale in the treatment of melanoma. Int J Hematol 2001;73:157-161
32. Zacharski LR, Henderson WG, Rickles FR, et al. Effect of sodium warfarin on survival in small cell carcinoma of the lung. JAMA 1981;245:831-835
33. Chahinian AP, Propert KJ, Ware JH, et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 1989;7:993-1002
34. Maurer LH, Herndon JE II, Hollis DR, et al. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited stage small cell lung cancer: CALGB protocol 8534. J Clin Oncol 1997;15:3378-3387
35. Lebeau B, Chastang C, Brechot J-M, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer 1994;74:38-45
36. Calvo FA, Hidalgo OF, Gonzales F, et al. Urokinase combination chemotherapy in small cell lung cancer. A phase II study. Cancer 1992;70:2624-2630
37. Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck and prostate: final report of VA Cooperative Study #75. Cancer 1984;53:2046-2052
38. Prandoni P, Lensing AW, Cogo S, et al. The long-term course of acute deep vein thrombosis. Ann Intern Med 1996;125:1-7
39. Lyberg T, Prydz H. Phorbol esters induce synthesis of thromboplastin activity in human monocytes. Biochem J 1981;194:699-706
40. Pangasnan RS, Deversux D, DeCunzo LP, Karp GI. The production of a factor X activator by a methylcholanthrene-induced rat fibrosarcoma. Thromb Haemost 1992;68:407-412
41. Zacharski LR, Costantini V, Moritz TE, Haakenson CM. Chronic nonsteroidal anti-inflammatory drug use in a cohort of patients with advanced lung and colon cancer. In: Honn KV, Nigam S, Walden T, eds. Prostaglandins, Leukotrienes and Cancer. Dordrecht, The Netherlands: Kluwer; 1991:497-501
42. Hawk ET, Viner JL, Dunnenberg A, DuBois RN. COX-2 in cancer - a player that's defining the rules. J Natl Cancer Inst 2002;94:545-546
43. Blanke CD. Celecoxib with chemotherapy in colorectal cancer. Oncology 2002;16(Suppl):17-21
44. Schulman S, Lindmaker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. N Engl J Med 2000;342:1953-1958
45. Zacharski LR, Ornstein DL. Venous thromboembolism and cancer. N Engl J Med 2000;343:1337-1338
46. Sciumbata T, Pirovano P, Pozzi P, et al. Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival. Invasion Metastasis 1996;16:132-143
47. von Tempelhoff G-F, Harenberg J, Niemann F, et al. Effect of low molecular weight heparin (Cetoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol 2000;16:815-824
48. Zacharski LR, Henderson WB. Vitamin K antagonists and cancer survival. Thromb Haemost 2002;88:173-174
49. Dvorak HF. Tumors: wounds that do not heal. N Engl J Med 1986;315:1650-1659
50. Gordon BL. Is intelligent design science? The scientific status and future of design theory explanation. In: Dembski WA, Kushiner JM, eds. Signs of Intelligence. Grand Rapids, MI: Brazos Press; 2001